Press Releases

The Joint Corp. Reports Second Quarter 2017 Financial Results

Revenue Increased 21% to $6.0 Million Compared to Prior Year Period

 Added 11 New Franchised Clinics in Second Quarter

Reaffirmed 2017 Guidance

Matthew E. Rubel Appointed Lead Director

SCOTTSDALE, Ariz., Aug. 10, 2017 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager and franchisor of chiropractic clinics, today reported results for the quarter ended June 30, 2017.    

Second Quarter 2017 Financial Highlights

  • Revenue increased 21% in the second quarter to $6.0 million, up from $5.0 million in the prior year second quarter
  • System-wide comp sales1 were 19%
  • Net loss improved 69% compared to the same quarter last year to ($1.0) million
  • Adjusted EBITDA was ($0.3) million in the second quarter, an 82% improvement compared to ($2.0) million in the same quarter last year
  • Added 11 new franchised clinics, ending the second quarter of 2017 with 383 total clinics in operation, a net increase of 42 clinics from June 30, 2016

“Positive trends continued throughout our operations during the second quarter,” said Peter D. Holt, president and chief executive officer of The Joint Corp. “Our revenue grew by 21%, we experienced our sixth consecutive quarterly improvement in Adjusted EBITDA, and our cash balance improved on a sequential quarter to quarter basis. We made further progress on our growth goals with the opening of 11 new franchises in the second quarter. Additionally, we sold two new regional developer licenses, and continued improvement in the operating performance of our company clinics, all of which positions us for accelerated growth.”

Holt added, “System-wide comp sales were up 19%, which reflects the growing market acceptance of our chiropractic services. For the remainder of the year, we are focused on achieving company-wide profitability and expanding our franchise network by adding 50 to 60 new franchised clinics in 2017.”    

1 Comp sales refers to the amount of sales a clinic generates in the most recent accounting period, compared to sales in the comparable period of the prior year, and (i) includes sales only from clinics that have been open at least 13 full months and (ii) excludes any clinics that have closed.

Second Quarter 2017 Financial Results

Revenue for the second quarter of 2017 increased 21% to $6.0 million from $5.0 million in the second quarter of 2016 due primarily to the net increase of 56 franchised clinics and increasing sales in our existing company-owned or managed clinics since June 30, 2016.

Cost of revenue in the second quarter of 2017 increased 6% compared to the second quarter of 2016 due primarily to higher regional developer royalties from increased sales of franchises.

Selling and marketing expenses decreased by 10% to $1.1 million in the second quarter of 2017, compared to $1.2 million in the same period last year due primarily to 14 fewer corporate clinics in the second quarter of 2017 compared to the same period last year.

General and administrative expenses decreased to $4.7 million in the second quarter of 2017, compared to $5.6 million in the second quarter of 2016 due to lower payroll and occupancy costs from 14 fewer corporate clinics in the second quarter of 2017 compared to the second quarter of 2016. In addition, the second quarter of 2016 was negatively impacted by a $0.3 million charge related to halting greenfield clinic development.

Total depreciation and amortization expense decreased for the second quarter of 2017, compared to the prior year quarter due to the aforementioned 14 fewer clinics in the 2017 second quarter compared to the same quarter last year.

Net loss in the second quarter of 2017 was ($1.0) million, or ($0.08) per share, compared to a net loss of ($3.3) million, or ($0.26) per share, in the same period last year.

Adjusted EBITDA (a non-GAAP measure) in the second quarter of 2017 was ($0.3) million, an 82% improvement compared to ($2.0) million in the same quarter last year. 

As of June 30, 2017, cash and cash equivalents were $3.0 million, compared to $3.0 million at December 31, 2016.  Pursuant to the terms of our credit agreement, during the first quarter of 2017, we borrowed a required $1.0 million on our line of credit, which remains unused as part of cash and cash equivalents on our balance sheet as of June 30, 2017.

Effective August 8, 2017, newly elected board member Matthew E. Rubel was appointed Lead Director of The Joint Corp. Rubel brings extensive C-suite and public company board experience to The Joint Corp., and most recently served as chief executive officer, president and board member of Varsity Brands, Inc. From 2005 to 2011 he served as chief executive officer and president of Collective Brands, Inc. Rubel succeeds Ronald V. DaVella as Lead Director who will remain on the Company’s board of directors and remain chairperson of the Company’s audit committee.

2017 Financial Guidance

For full year 2017, we are reiterating our guidance set forth below:

  • Total revenues in the range of $22 million to $24 million
  • Adjusted EBITDA in the range of ($1.5) million to ($0.5) million
  • Net new franchised clinic openings in the range of 50 to 60

Conference Call

The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, August 10, 2017, to discuss the second quarter 2017 results. The conference call may be accessed by dialing 765-507-2604 or 844-464-3931, and referencing 41541211. A live webcast of the conference call will also be available on the investor relations section of the Company’s website at An audio replay will be available two hours after the conclusion of the call through August 17, 2017. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 41541211.

Non-GAAP Financial Information

This earnings release includes a presentation of EBITDA and Adjusted EBITDA which are non-GAAP financial measures. These are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company’s underlying operating performance and operating trends. Reconciliation of net loss to EBITDA and Adjusted EBITDA is presented in the table below. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, loss on disposition or impairment, and stock-based compensation expenses. The Company defines EBITDA as net income (loss) before net interest, tax expense, depreciation, and amortization expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company’s financial statements filed with the SEC.

Forward-Looking Statements

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our failure to develop or acquire corporate clinics as rapidly as we intend, our failure to profitably operate corporate clinics, and the factors described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ:JYNT)

Based in Scottsdale, Arizona, The Joint is an emerging growth company that is reinventing chiropractic by making quality care convenient and affordable for patients seeking pain relief and ongoing wellness. Its no-appointment policy and convenient hours and locations make care more accessible, and affordable membership plans and packages eliminate the need for insurance. With nearly 400 clinics nationwide and more than 4 million patient visits annually, The Joint is a key leader in the chiropractic profession. For more information, visit or follow the brand on Twitter, Facebook, YouTube and LinkedIn.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Florida, Illinois, Kansas, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee and Washington, The Joint and its franchisees provide management services to affiliated professional chiropractic practices.

    June 30,   December 31,
    2017   2016
ASSETS   (unaudited)    
Current assets:                
Cash and cash equivalents   $ 3,046,777     $ 3,009,864  
Restricted cash     280,414       334,394  
Accounts receivable, net     1,135,574       1,021,733  
Income taxes receivable     3,054       42,014  
Notes receivable - current portion     53,475       40,826  
Deferred franchise costs - current portion     516,981       748,300  
Prepaid expenses and other current assets     557,246       499,525  
Total current assets     5,593,521       5,696,656  
Property and equipment, net     4,071,501       4,724,706  
Notes receivable, net of current portion     148,525       -  
Deferred franchise costs, net of current portion     887,900       836,350  
Intangible assets, net     2,017,169       2,338,922  
Goodwill     2,750,338       2,750,338  
Deposits and other assets     657,202       707,889  
Total assets   $ 16,126,156     $ 17,054,861  
Current liabilities:                
Accounts payable   $ 971,326     $ 1,054,946  
Accrued expenses     267,425       299,997  
Co-op funds liability     82,583       73,246  
Payroll liabilities     609,544       750,421  
Notes payable - current portion     100,000       331,500  
Deferred rent - current portion     146,618       215,450  
Deferred revenue - current portion     2,360,516       3,077,430  
Other current liabilities     52,071       60,894  
Total current liabilities     4,590,083       5,863,884  
Revolving credit - notes payable     1,000,000       -  
Deferred rent, net of current portion     875,845       1,400,790  
Deferred revenue, net of current portion     3,876,388       2,231,712  
Deferred tax liability     176,032       120,700  
Other liabilities     1,030,003       512,362  
Total liabilities     11,548,351       10,129,448  
Commitments and contingencies                
Stockholders' equity:                
Series A preferred stock, $0.001 par value; 50,000                
shares authorized, 0 issued and outstanding, as of June 30, 2017,                
and  December 31, 2016     -       -  
Common stock, $0.001 par value; 20,000,000 shares                
authorized, 13,461,044 shares issued and 13,164,540 shares outstanding                
as of June 30, 2017 and 13,317,393 shares issued and 13,020,889                
outstanding as of December 31, 2016     13,461       13,317  
Additional paid-in capital     36,709,063       36,398,588  
Treasury stock, at cost, 296,504 shares as of June 30, 2017                
and December 31, 2016     (503,118 )     (503,118 )
Accumulated deficit     (31,641,601 )     (28,983,374 )
Total stockholders' equity     4,577,805       6,925,413  
Total liabilities and stockholders' equity   $ 16,126,156     $ 17,054,861  


    Three Months Ended   Six Months Ended
    June 30,   June 30,
    2017   2016   2017   2016
Revenues and management fees from company clinics   $ 2,707,458     $ 2,137,252     $ 5,223,059     $ 3,795,805  
Royalty fees     1,854,087       1,428,548       3,560,160       2,797,379  
Franchise fees     357,600       524,209       807,100       1,039,009  
Advertising fund revenue     621,578       356,580       1,220,014       622,301  
IT related income and software fees     282,525       229,400       549,538       450,534  
Regional developer fees     119,733       225,080       196,629       372,617  
Other revenues     71,827       72,972       132,165       161,432  
Total revenues     6,014,808       4,974,041       11,688,665       9,239,077  
Cost of revenues:                                
Franchise cost of revenues     704,767       668,851       1,388,010       1,363,586  
IT cost of revenues     65,452       58,888       124,313       104,116  
Total cost of revenues     770,219       727,739       1,512,323       1,467,702  
Selling and marketing expenses     1,058,224       1,174,178       2,016,930       1,912,861  
Depreciation and amortization     503,226       637,115       1,081,212       1,212,659  
General and administrative expenses     4,667,688       5,621,771       9,231,768       11,313,826  
Total selling, general and administrative expenses     6,229,138       7,433,064       12,329,910       14,439,346  
Loss on disposition or impairment     -       -       417,971       -  
Loss from operations     (984,549 )     (3,186,762 )     (2,571,539 )     (6,667,971 )
Other (expense) income, net     (24,030 )     (1,150 )     (43,496 )     (677 )
Loss before income tax expense     (1,008,579 )     (3,187,912 )     (2,615,035 )     (6,668,648 )
Income tax expense     (2,583 )     (73,470 )     (43,192 )     (117,867 )
Net loss and comprehensive loss   $ (1,011,162 )   $ (3,261,382 )   $ (2,658,227 )   $ (6,786,515 )
Loss per share:                                
Basic and diluted loss per share   $ (0.08 )   $ (0.26 )   $ (0.20 )   $ (0.54 )
Basic and diluted weighted average shares     13,127,255       12,672,974       13,085,159       12,620,438  
Non-GAAP Financial Data:                                
Net income (loss)   $ (1,011,162 )   $ (3,261,382 )   $ (2,658,227 )   $ (6,786,515 )
Interest expense     25,000       4,225       50,000       8,676  
Depreciation and amoritzation expense     503,226       637,115       1,081,212       1,212,659  
Tax expense (benefit) penalties and interest     2,583       73,470       43,192       117,867  
EBITDA   $ (480,353 )   $ (2,546,572 )   $ (1,483,823 )   $ (5,447,313 )
Stock compensation expense     132,056       559,726       227,121       757,394  
Acquisition related expenses     492       18,958       13,142       49,818  
Loss on disposition or impairment     -       -       417,971       -  
Adjusted EBITDA   $ (347,806 )   $ (1,967,889 )   $ (825,590 )   $ (4,640,100 )

 The above table represents the reconciliation of net income (loss) to Adjusted EBITDA for the three and six month periods ended June 30, 2017 and 2016.

    Six Months Ended
    June 30,
    2017    2016 
Net loss   $   (2,658,227 )   $   (6,786,515 )
Adjustments to reconcile net loss to net cash     1,695,104       1,636,564  
Changes in operating assets and liabilities       228,466         (2,905,287 )
Net cash used in operating activities       (734,657 )       (8,055,238 )
Net cash used in investing activities       (80,428 )       (2,465,949 )
Net cash provided by (used in) financing activities       851,998         (152,900 )
Net increase (decrease) in cash   $   36,913     $   (10,674,087 )
Investor Contact:
Peter Vozzo
[email protected]

Primary Logo

Source: The Joint Corp.